ATRA
Atara Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.69
−0.21%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.13
- Revenue estimate
- $800.0K
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.32
- EPS estimate
- -$0.32
- Revenue actual
- $630.0K
- Revenue estimate
- $550.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +7.4%
- Revenue beats (12Q)
- 7
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.32 | -$0.32 | Miss -1.59% | $630.0K |
| May 12, 2026 | -$0.33 | -$0.29 | Beat 12.00% | $516.0K |
| Mar 16, 2026 | -$0.18 | -$0.25 | Miss -42.13% | $1.6M |
| Nov 12, 2025 | -$0.83 | -$0.32 | Beat 61.45% | $3.5M |
| May 15, 2025 | -$3.07 | $3.50 | Beat 214.01% | $98.1M |
| Mar 7, 2025 | -$3.82 | -$1.19 | Beat 68.85% | $32.8M |
| May 9, 2024 | -$9.25 | -$5.75 | Beat 37.84% | $27.4M |
| Nov 1, 2023 | -$16 | -$17 | Miss -4.76% | $2.1M |
| Feb 8, 2023 | -$15 | -$18 | Miss -18.03% | — |
| May 5, 2022 | -$25 | -$22 | Beat 11.22% | $7.3M |
| Feb 28, 2022 | -$15 | -$24 | Miss -60.00% | $7.5M |
| Nov 4, 2021 | -$23 | -$23 | Beat 2.17% | $5.4M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026